

Contents

Published by Cedilla Publishing Limited
PO Box 58871, London SE15 9BE, UK
Telephone: +44 (0)7794 485294
www.cedillapublishing.com

© 2008, 2010 Cedilla Publishing Limited

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the written permission of the copyright owner.

The publisher and authors have made every effort to ensure the accuracy of the information in this book, but cannot accept responsibility for any errors or omissions. Any product mentioned in this publication should be used in accordance with the local prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

British Library Cataloguing in Publication Data

A catalogue for this book is available from the British Library.

ISBN: 978-1-905982-06-6 second edition
(978-1-905982-03-5 first edition)

10 9 8 7 6 5 4 3 2 1

Cover image: Fat cells

Manfred Kage, Peter Arnold Inc. / Science Photo Library

Printed by Halstan Ideal in the UK.

| | |
|---|-------------|
| Abbreviations | vi |
| Preface | vii |
| Acknowledgements | viii |
| 1. Major primary prevention trials with statins | 1 |
| West Of Scotland Coronary Prevention Study (WOSCOPS) | 2 |
| Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) | 4 |
| Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial—Lipid-Lowering Trial (ALLHAT—LLT) | 6 |
| PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) | 8 |
| Primary prevention of CV disease with pravastatin in Japan (MEGA) | 10 |
| Primary prevention of CV disease with statin therapy: a meta-analysis of randomized controlled trials | 12 |
| Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) | 14 |
| 2. Major secondary prevention trials with statins | 17 |
| Scandinavian Simvastatin Survival Study (4S) | 18 |
| Cholesterol and Recurrent Events (CARE) | 20 |
| Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) | 22 |
| Heart Protection Study (HPS) | 24 |
| 3. Early statin treatment in ACS patients | 27 |
| Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) | 28 |
| Effects of early treatment with statins on short-term clinical outcomes in ACS: a meta-analysis of randomized controlled trials | 30 |
| Atorvastatin for Reduction of Myocardial Damage during Angioplasty (ARMYDA)—ACS | 32 |
| 4. CHD prevention trials with statins in patients with diabetes or the metabolic syndrome | 35 |
| HPS diabetes subgroup analysis | 36 |
| LIPID post-hoc subgroup analysis | 38 |
| Collaborative Atorvastatin Diabetes Study (CARDS) | 40 |
| Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT—LLA) post-hoc diabetes subgroup analysis | 42 |
| Treating to New Targets (TNT) diabetes subgroup analysis | 44 |
| TNT post-hoc metabolic syndrome subgroup analysis | 46 |

| | | | |
|---|-----------|--|------------|
| Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN) | 48 | 8. Meta-analyses for efficacy, safety and cost–benefit calculations | 101 |
| 5. CHD prevention in chronic kidney disease | 51 | Cholesterol Treatment Trialists (CTT) | 102 |
| Die Deutsche Diabetes Dialyse (4D) Studie | 52 | Aspirin, statins or both drugs for the primary prevention of CHD events in men: a cost–utility analysis | 104 |
| 4S post-hoc mild chronic renal insufficiency subgroup analysis | 54 | Analyses of cancer data from three ezetimibe trials | 106 |
| Statins and CV RR in patients with chronic kidney disease and end-stage renal failure | 56 | Primary prevention strategies for lipid lowering: a meta-analysis | 108 |
| 6. Stroke prevention | 59 | 9. Primary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL | 111 |
| Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) | 60 | World Health Organization (WHO) clofibrate study | 112 |
| Impact of statins on risk of stroke | 62 | Helsinki Heart Study (HHS) | 114 |
| 7. Comparative hypolipidaemic efficacy, IVUS, IMT and end-point trials | 65 | Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) | 116 |
| Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (CURVES) | 66 | 10. Secondary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL | 119 |
| Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) | 68 | Coronary Drug Project | 120 |
| Statin Therapies for Elevated Lipid Levels compared Across dose ranges to Rosuvastatin (STELLAR) | 70 | Veterans Affairs HDL Intervention Trial (VA-HIT) | 122 |
| Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY I) | 72 | Bezafibrate Infarction Prevention (BIP) | 124 |
| Reversal of atherosclerosis with aggressive lipid lowering therapy (REVERSAL) | 74 | HDL Atherosclerosis Treatment Study (HATS) | 126 |
| PRavastatin Or atorVastatin Evaluation and Infection Therapy—Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22) | 76 | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) | 128 |
| VYtorin Versus Atorvastatin (VYVA) | 78 | Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) | 130 |
| Ezetimibe Add-on to Statin for Effectiveness (EASE) | 80 | Appendix: conversion calculator | 132 |
| TNT | 82 | | |
| Incremental Decrease in End points through Aggressive Lipid lowering (IDEAL) | 84 | | |
| VYTAL study | 86 | | |
| A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) | 88 | | |
| Meta-analysis of CV outcomes trials comparing intensive vs moderate statin therapy | 90 | | |
| Measuring Effects on intima–media Thickness: an Evaluation Of Rosuvastatin (METEOR) | 92 | | |
| Ezetimibe aNd simvastatin in Hypercholesterolemia enhANces atherosClerosis rEgression (ENHANCE) | 94 | | |
| Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) | 96 | | |
| Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol 6–HDL And LDL Treatment Strategies (ARBITER6–HALTS) | 98 | | |